Published in Circ Cardiovasc Qual Outcomes on November 09, 2008
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med (2009) 7.62
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA (2012) 6.29
Predicting the 30-year risk of cardiovascular disease: the framingham heart study. Circulation (2009) 4.62
Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med (2010) 3.57
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol (2010) 2.07
Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. Circulation (2011) 1.88
Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation (2011) 1.77
Assessing salivary C-reactive protein: longitudinal associations with systemic inflammation and cardiovascular disease risk in women exposed to intimate partner violence. Brain Behav Immun (2012) 1.77
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J (2011) 1.66
Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol (2012) 1.63
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J (2013) 1.60
The influence of hip circumference on the relationship between abdominal obesity and mortality. Int J Epidemiol (2012) 1.21
Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc (2014) 1.14
Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol (2013) 1.12
Cardiovascular risk assessment--from individual risk prediction to estimation of global risk and change in risk in the population. BMC Med (2010) 1.08
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol (2011) 1.01
Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol (2013) 1.00
Detection of homocysteine and C-reactive protein in the saliva of healthy adults: comparison with blood levels. Biomark Insights (2010) 0.99
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc (2013) 0.96
Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction. Can J Cardiol (2009) 0.95
Comorbidity in inflammatory bowel disease. World J Gastroenterol (2011) 0.93
Methods for evaluating novel biomarkers - a new paradigm. Int J Clin Pract (2010) 0.91
The combination of abdominal obesity and high-sensitivity C-reactive protein predicts new-onset hypertension in the general Japanese population: the Tanno-Sobetsu study. Hypertens Res (2015) 0.91
Elevated pulmonary artery systolic pressure predicts heart failure admissions in African Americans: Jackson Heart Study. Circ Heart Fail (2014) 0.91
Coronary risk assessment by point-based vs. equation-based Framingham models: significant implications for clinical care. J Gen Intern Med (2010) 0.90
Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice? PLoS Med (2010) 0.89
Early identification of atherosclerotic disease by noninvasive imaging. Nat Rev Cardiol (2010) 0.87
Impaired retinal vasodilator responses in prediabetes and type 2 diabetes. Acta Ophthalmol (2013) 0.86
Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Rep (2015) 0.84
Quantifying cardiometabolic risk using modifiable non-self-reported risk factors. Am J Prev Med (2014) 0.83
Relationships among changes in C-reactive protein and cardiovascular disease risk factors with lifestyle interventions. Nutr Metab Cardiovasc Dis (2012) 0.81
Atherosclerotic biomarkers and aortic atherosclerosis by cardiovascular magnetic resonance imaging in the Framingham Heart Study. J Am Heart Assoc (2013) 0.81
Evidence of lung function for stratification of cardiovascular disease risk. Korean Circ J (2011) 0.81
CVD screening in low-risk, asymptomatic adults: clinical trials needed. Nat Rev Cardiol (2012) 0.80
Exploring the complexity of cardiometabolic risk in women. Biol Res Nurs (2011) 0.79
Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction. Trends Cardiovasc Med (2011) 0.78
Use and Customization of Risk Scores for Predicting Cardiovascular Events Using Electronic Health Record Data. J Am Heart Assoc (2017) 0.78
Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness. Int J Epidemiol (2009) 0.77
Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis. Circulation (2011) 0.77
Alteration of some inflammatory biomarkers by dietary oxysterols in rats. Inflammation (2012) 0.76
Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study. Arch Med Sci (2016) 0.75
Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality. Transplantation (2013) 0.75
Diagnosis of Coronary Heart Diseases Using Gene Expression Profiling; Stable Coronary Artery Disease, Cardiac Ischemia with and without Myocardial Necrosis. PLoS One (2016) 0.75
Novel treatments for cardiovascular disease prevention. Cardiovasc Ther (2011) 0.75
Prognostic Importance of C-Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study. J Am Heart Assoc (2016) 0.75
[Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis]. Z Rheumatol (2012) 0.75
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation (2007) 20.44
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA (2001) 17.91
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol (2004) 12.03
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
The Framingham Offspring Study. Design and preliminary data. Prev Med (1975) 10.53
Probability of stroke: a risk profile from the Framingham Study. Stroke (1991) 10.14
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA (1993) 5.21
Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med (1995) 4.36
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med (2005) 3.31
Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation (2001) 2.93
Novel clinical markers of vascular wall inflammation. Circ Res (2001) 2.80
Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation (1997) 2.29
C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J (2002) 1.99
Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol (2005) 1.88
Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol (1980) 1.87
Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med (1999) 1.51
C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation (2002) 1.46
Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation (2003) 1.33
Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA (2003) 1.30
Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med (1991) 1.22
34th Bethesda Conference: Task force #4--How do we select patients for atherosclerosis imaging? J Am Coll Cardiol (2003) 0.97
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics (2008) 15.77
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet (2009) 8.42
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
The prevention and treatment of missing data in clinical trials. N Engl J Med (2012) 6.92
A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet (2006) 6.39
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation (2008) 5.95
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging (2005) 5.84
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet (2009) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation (2007) 5.10
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
An open access database of genome-wide association results. BMC Med Genet (2009) 4.61
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 4.58
Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr (2007) 4.37
Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med (2004) 4.34
Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet (2009) 4.28
A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A (2002) 4.22
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry (2012) 3.73
Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology (2010) 3.60
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med (2003) 3.54
Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J (2009) 3.54
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Neck circumference as a novel measure of cardiometabolic risk: the Framingham Heart study. J Clin Endocrinol Metab (2010) 3.39
On the replication of genetic associations: timing can be everything! Am J Hum Genet (2008) 3.32
C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med (2005) 3.31
Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest (2011) 3.23
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
NRXN3 is a novel locus for waist circumference: a genome-wide association study from the CHARGE Consortium. PLoS Genet (2009) 3.18
Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med (2005) 3.17
Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation (2006) 3.15
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Visceral fat is associated with lower brain volume in healthy middle-aged adults. Ann Neurol (2010) 3.05
Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02
Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet (2007) 2.93
Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst (2003) 2.92
A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev (2007) 2.91
Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke (2008) 2.84
Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry (2013) 2.80
Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation (2010) 2.78
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet (2010) 2.76
Accuracy of offspring reports of parental cardiovascular disease history: the Framingham Offspring Study. Ann Intern Med (2004) 2.74
Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes (2009) 2.70
Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. PLoS One (2013) 2.65
Long-term trends in myocardial infarction incidence and case fatality in the National Heart, Lung, and Blood Institute's Framingham Heart study. Circulation (2009) 2.63
Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat Genet (2013) 2.62
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation (2011) 2.62
Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med (2010) 2.55
Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation (2012) 2.51
Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring) (2010) 2.42
The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes (2006) 2.40
Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study. Circulation (2003) 2.39
The association of a SNP upstream of INSIG2 with body mass index is reproduced in several but not all cohorts. PLoS Genet (2007) 2.35
Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation (2004) 2.35
Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol (2002) 2.33
Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation (2010) 2.32
Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med (2005) 2.29
Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest (2003) 2.27
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Defining normal distributions of coronary artery calcium in women and men (from the Framingham Heart Study). Am J Cardiol (2008) 2.26
Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr (2006) 2.25
Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? Circulation (2010) 2.25
Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24
One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics (2007) 2.20
Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation (2006) 2.18